OBJECTIVE -The aim of this study was to investigate the pharmacokinetics, postprandial blood glucose excursions, and safety of insulin glulisine as compared with regular human insulin (RHI), both administered immediately before meals in pediatric patients with type 1 diabetes.
RESEARCH DESIGN AND METHODS-A total of 10 children (aged 5-11 years) and 10 adolescents (aged 12-17 years) were enrolled in a randomized, single-center, single-dose, double-blind, cross-over study. The blood glucose of fasting patients was stabilized with intravenous insulin, following which patients received 0.15 IU/kg of subcutaneously injected insulin glulisine or RHI 2 min before a weight-adjusted standardized liquid meal.RESULTS -For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 IU/ml, P Ͻ 0.05) and initial insulin concentrations (insulin [area under the curve] AUC 0 -2h 5,232 vs. 2,994 IU ⅐ min Ϫ1 ⅐ ml Ϫ1 , P Ͻ 0.05; data are geometric means) were higher after insulin glulisine than RHI. Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P Ͻ 0.05) were shorter with insulin glulisine versus RHI. Postprandial glucose excursions after insulin glulisine were lower than after RHI (glucose AUC 0 -6h 641 vs. 801 mg ⅐ h Ϫ1 ⅐ dl Ϫ1 , P Ͻ 0.05). The pharmacokinetic profile for insulin glulisine was similar for children and adolescents, whereas the pharmacokinetic profile for RHI demonstrated a 64% higher concentration in adolescents. Insulin glulisine was safe and well tolerated.CONCLUSIONS -The rapid-acting properties of insulin glulisine that have been previously demonstrated in adults are also observed in children and adolescents with type 1 diabetes. Further, these initial data indicate that insulin glulisine is safe and well tolerated in this patient population.
Diabetes Care 28:2100 -2105, 2005T he goal of basal-bolus insulin therapy in type 1 diabetes is to achieve near to normal glycemic control and reduce the risk of long-term clinical complications (1). Children and adolescents sometimes encounter difficulties in adjusting their daily activities to fixed intervals between insulin administration and meals, particularly with regular human insulin (RHI), which requires administration 30 -45 min before mealtime (2). The use of rapid-acting insulin analogs instead of RHI for prandial glycemic control is becoming increasingly accepted, since these insulins can be given much closer to mealtime (2-4). Thus, rapid-acting insulin analogs might offer advantages, particularly for very young children in whom the actual carbohydrate intake is often difficult to predict (5). It remains to be shown, however, whether the rapidacting properties of these analogs are preserved in children.Insulin glulisine ([LysB3, GluB29]-insulin) is a recombinant insulin analog designed to provide the same total glucodynamic effect as RHI after subcutaneous administration but with a faster onset and shorter duration of action (6), which has been demonstrated in adults (7-9). The altered absorpt...